Filing Flows › BillionToOne (BLLN) › Q3 2026 › vs Q3 2025
BillionToOne (BLLN) Q3 2026 vs Q3 2025 (year over year)
BillionToOne's revenue rose $39.5M (+47%) from $83.5M in Q3 2025 to $123M in Q3 2026. The biggest changes: Prenatal +$30.2M (+41%); Oncology +$8.4M (+96%); Clinical trial support and other services +$877K (+115%). Gross margin 70.9% against 69.9% (+0.9 pts).
BillionToOne, Q3 2026: revenue $123M (+47% year over year), operating margin 9.0%, net earnings $17.4M, operating cash flow $12.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 70.9% | 69.9% | +0.9 pts |
| Operating margin | 9.0% | 11.5% | -2.6 pts |
| Net margin | 14.1% | 6.8% | +7.3 pts |
| Free cash flow margin | 7.0% | 9.4% | -2.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Prenatal | $104M | $74.1M | $30.2M | +41% |
| Oncology | $17.1M | $8.7M | $8.4M | +96% |
| Clinical trial support and other services | $1.6M | $761K | $877K | +115% |
| Revenue | $123M | $83.5M | $39.5M | +47% |
| Gross profit | $87.1M | $58.4M | $28.7M | +49% |
| Cost of revenue | $35.8M | $25.1M | $10.7M | +43% |
| Other income, net | $6.4M | −$4.1M | $10.4M | — |
| Operating profit | $11.0M | $9.6M | $1.4M | +14% |
| Operating expenses | $76.1M | $48.8M | $27.3M | +56% |
| Pre-tax earnings | $17.4M | $5.6M | $11.8M | +212% |
| Research & development | $20.2M | $13.0M | $7.3M | +56% |
| SG&A | $55.9M | $35.8M | $20.1M | +56% |
| Net earnings | $17.4M | $5.7M | $11.7M | +205% |
| Income tax | $1K | −$129K | $130K | — |
| Depreciation & amortization | $2.0M | $1.7M | $281K | +17% |
| Share-based compensation | $9.7M | $4.5M | $5.2M | +117% |
| Working capital & other | $16.5M | $1.9M | $14.6M | +778% |
| Operating cash flow | $12.5M | $10.0M | $2.6M | +26% |
| Free cash flow (company-reported) | $8.6M | $7.9M | $728K | +9% |
| Purchases of property and equipment | $3.9M | $2.1M | $1.8M | +86% |
Questions
How much did BillionToOne's revenue grow year over year in Q3 2026?
BillionToOne's revenue rose $39.5M (+47%) from $83.5M in Q3 2025 to $123M in Q3 2026.
What drove BillionToOne's revenue change in Q3 2026?
Prenatal +$30.2M (+41%); Oncology +$8.4M (+96%); Clinical trial support and other services +$877K (+115%).